145
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      scite_
       
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Choosing contralateral prophylactic mastectomy for unilateral breast cancer in an urban South African breast cancer clinic

      Published
      research-article
      Bookmark

            Abstract

            Background: International trends have shown that female patients with unilateral breast cancer are electing bilateral mastectomies as a prophylactic measure. The study aimed to determine the prevalence of unilateral mastectomies (UM) with and without contralateral prophylactic mastectomy (CPM) and to identify whether demographic and pathological characteristics predict the choice of CPM.

            Methods: A record review of demographic details and pathological results of all female patients undergoing mastectomy for unilateral breast cancer from 2013-2015 was conducted at the Helen Joseph Breast Care Clinic in Johannesburg, South Africa.

            Results: A total of 299 women who had mastectomies for unilateral breast cancer were included in the study. Of these, 59 had CPM (19.7%). Significantly more White women opted for a CPM than Black women (43.5% vs 10.6%, p♯αμπ;λτ;0.0001). Women who underwent CPM were significantly younger, and there was a trend for higher median breast weight than patients who only underwent UM (p = 0.03 and p = 0.09, respectively). There was no difference between the two groups with regard to patient income status, tumour histology, TNM stage or neoadjuvant chemotherapy.

            Conclusion: The demographic and histopathological characteristics of breast cancer which influence the choice of CPM in the South African context have some similarities to those in the international literature in that White and younger women more often choose CPM compared to other racial groups. The more advanced stages of breast cancer presentation in our study suggest that public health awareness and screening measures need to be significantly strengthened in South Africa.

            Main article text

            Introduction

            Background

            Breast cancer is the most frequently diagnosed and leading cause of death in women.(1) Over the recent past, there has been an increase in the number of women electing contralateral prophylactic mastectomy (CPM) in unilateral breast cancer.(2) In 2018, breast cancer ranked first in the number of new cases and third in the number of deaths in South Africa. The International Agency for Research on Cancer reported 14,097 new cases and a 5-year prevalence of 37 662 people across all ages.(3)

            In developing countries, rapid societal and economic changes are potential reasons for lifestyle trends to shift towards those in high-income countries.(4) These lifestyle trends have led to an increase in the burden of cancers associated with reproductive, dietary, and hormonal factors such as breast cancer.(4)

            In women who are diagnosed with unilateral breast cancer, the risk of developing contralateral breast cancer is three to five times higher than those women who do not have breast cancer, with even higher risk in women with either BRCA1 or BRCA2 gene mutations.(5) Tumour suppressor genes, BRCA1 and BRCA2 germline mutations pose the most significant risk factor for breast and ovarian cancer.(6) The lifetime risk of contralateral breast cancer is 40-65% in women with this mutation, and it is in this demographic that CPM has the most significant potential benefit.(7) Elsayegh et al. explored the benefit of CPM in women with unilateral breast cancer and a germline BRCA1/2 mutation. They found that the risk of developing metachronous contralateral cancer was reduced by 91%.(10) The reported tumour characteristics associated with increased CPM rates have been a clinically higher tumour stage, multicentric primary tumour, invasive and in situ lobular histology and recent year of diagnosis.(8)

            In women without a known predisposition, the annual risk of metachronous development of clinically detected contralateral breast cancer is about 0.6%.(9) In the United States, in women of all ages, the rate of CPM increased from 1.9% in 1998 to 10.2% in 2011 and much higher rates in women under 45 years of age, rising from 3.7% in 1998 to 26.2% in 2011.(9) These rates appear to be out of proportion to the reported risks of metachronous cancer.(9)

            Several reports have identified demographic, histopathological/oncological characteristics and psychological factors of patients who chose CPM in unilateral breast cancer. Factors identified from these three distinct but often overlapping groups are summarised in Table 1. A fourth factor of cosmetic symmetry may also be important in some patients.

            Table 1:
            Factors associated with the increasing trend of contralateral prophylactic mastectomy
            DemographicHistopathological/OncologicalPsychological
            Young age (<45) (811)Stage 1-2 (4,9,1215)Fear of recurrence (13,1618)
            White (811,13,14)Invasive lobular (8,9,1113)Perceived benefit (16,17)
            High Socio-Economic Status (9,12,13)Small tumour size (<2 cm) (10)Influence by family/friends (17,18)
            Family History (7,10,13)Node negative (10)Over-estimation of risk (16,17,19)
            ER/PR negative (10)
            Radiation (10)
            First primary tumour (10)
            Neoadjuvant chemotherapy (12,15)
            BRCA 1/2 (12,13)

            The increase in the trend for CPM was also studied by Agarwal et al., who found a 3.5-fold increase from 1997 to 2005, with young age, family history, White ethnicity and the availability of immediate reconstruction being predictors of this choice.(10) Furthermore, it was found that the odds of CPM were independently increased by later years of diagnosis, lower stage, smaller tumour size, node-negative status, first primary cancer, higher median county income and a higher percentage of women with greater than 12 years of education. Among patients who underwent breast reconstruction, younger age, White race, and later year of diagnosis had higher odds of CPM.(10)

            Similarly, a 2015 report from the National Cancer Data Base in the USA found that a higher proportion of White women fell into a higher socioeconomic group, 15% more likely to have private medical insurance and thus more likely to choose CPM compared to their lower socioeconomic status counterparts who were predominantly Black, Asian and Hispanic.(9)

            Lizarraga et al. explored the risk of developing contralateral breast cancer by assessing specific demographics and tumour characteristics.(20) This particular breakdown is essential as it indicates to the health professional whether the patient choosing the procedure is justified in their reasons outside of the genetic risk and thus aids in the counselling, advice, and reassurance. They found that in the absence of genetic mutations, patients younger than 35 years with a strong family history and with oestrogen receptor-negative tumours have a higher incidence of contralateral breast cancer.(20) Also, White women were more likely to choose CPM than Black women.

            Covelli's group questioned women on the psychological aspects of their breast cancer diagnosis. All the patients reacted to the news of the diagnosis with shock and fear. The women said that despite being counselled that breast-conserving treatment versus unilateral mastectomy was equivalent in terms of long-term survival, they felt that the odds of survival were increased if all the breast tissue was gone. Women who were non-carriers of the genetic mutation, when answering a questionnaire, estimated the 5-year risk of contralateral breast cancer at 15% (instead of 0.6 %).(9) This misconception led to an increase in the choice of CPM.(16)

            The modern patient has increased access to information, which expands the influence in the decision-making relating to their disease. A recent study showed that patients were mainly influenced by breast surgeons, plastic surgeons and medical oncologists rather than TV, the internet, articles and magazines.(21)

            Determining the reasons behind the trend for choosing CPM is vital to address potential issues in patient counselling and peri-operative support in the future. Long-term survival after breast cancer means that surgical decisions have long-lasting consequences for patients. There is no data in South Africa on the oncological and demographic factors influencing the decision to choose CPM. This study thus aimed to ascertain characteristics in patients with unilateral breast cancer who chose CPM.

            Methods

            Study design

            The study was a retrospective, descriptive study of patients undergoing mastectomy for unilateral breast cancer, comparing those choosing UM with those choosing mastectomy with CPM as well. A record review of enrolled participants’ histological results and demographic details was conducted at the Breast Care Clinic of Helen Joseph Hospital, a medium-sized public hospital in Johannesburg, South Africa. The patient details and chosen surgery information were captured prospectively in the Breast Care Clinic database at the time of diagnosis.

            Data acquisition

            Female patients of all ages who underwent a mastectomy for unilateral breast cancer from 2013 to 2015 were included in the study.

            The hospital's billing system, the Uniform Patient Fee Schedule (UPFS) or “H” status, is the same that is used for all public sector hospitals in South Africa.(22) Patients are classified as full-paying or subsidized patients. The default classification for a person without income is H1. Subsidization depends on the assessment of income by the means test. We used “H” status as an indicator of socioeconomic status based on a patient's ability to pay the hospital fees. The patients fell into either H0, H1 or H2.(22)

            Each patient's pathology report was retrieved from the National Health Laboratory System's ‘Labtrak’ system. The information recorded included the following: number of specimens received; weight of the breast (in the case of two breasts, the CPM breast was recorded); histology of the CPM side; use of neoadjuvant chemotherapy; stage of breast cancer.

            Statistical analyses

            The data was captured in Microsoft Excel and exported into SPSS (Statistical Product and Service Solutions) software for data analysis. Descriptive statistics are reported as appropriate, including frequencies and percentages, means and standard deviations (SD) or median and interquartile ranges (IQR). The Mann-Whitney U test assessed whether the median age and weight differed significantly between the UM or CPM groups. The Chi-square or Fisher's Exact test of association was used, as appropriate, to determine associations between categorical variables according to UM or CPM groups. A p-value less or equal to 0.05 was considered statistically significant. Ethical approval for the study was obtained from the University of the Witwatersrand Human Research Ethics Committee (Medical).

            Results

            A total of 299 patients had mastectomies for unilateral breast cancer during the study period, of whom 59 (19.7%) had CPMs. The demographic and clinical information, including age, race, ‘H’ status and breast weight, are summarised in Table 2. There was a significant difference in the age of patients choosing unilateral versus CPM, with the UM patients being significantly older than the CPM patients (p = 0.03). Most patients were of low socioeconomic status (H1: 92.3%) (Table 2). Significantly more Black patients were classified as H1 compared to the other races at 96.5% vs 86.7%, respectively (p = 0.003). However, there was no difference in the H status of patients between the UM and CPM groups.

            Table 2:
            Patient demographics by CPM status
            ParameterAll (n = 299)UM (n = 240)CPM (n = 59)P-value
            Age (years), median (IQR)56.0 (44.0 – 65.0)56.0 (45.5 – 66.0)53.0 (41.0 – 62.0)0.03*
            Breast weight (grams), median (IQR)586 (371–933)577 (355-860)655 (462-1020)0.09
            Race, n (%) (n = 298)
                 Black170 (57.1%)152 (63.6%)18 (30.5%)<0.001**
                 Coloured43 (14.4%)35 (14.6%)8 (13.6%)
                 Indian16 (5.4%)13 (5.4%)3 (5.1%)
                 White69 (23.2%)39 (16.3%)30 (50.9%)
            H Status, n (%)***
                 H022 (7.4%)17 (7.1%)5 (8.5%)0.82
                 H1276 (92.3%)222 (92.5%)54 (91.5%)
                 H21 (0.3%)1 (0.4%)0 (0%)

            Abbreviations: IQR, interquartile range; CPM, contralateral prophylactic mastectomy; UM, unilateral mastectomy.

            *

            Mann-Whitney U test.

            **

            Chi2/Fisher's exact test.

            ***

            “H” status as an indicator of socioeconomic status based on the ability to pay the hospital fees, the patients fell into either H0, H1 or H2.

            The majority of patients in the study were Black (57.1%), followed by White (23.2%), Coloured (14.4%) and Indian (5.4%) patients. One patient's race was not documented. Overall, there was a highly significant difference in patients who chose UM vs CPM across racial groups (p♯αμπ;λτ;0.0001). (Figure 1) Specifically, only 10.6% of Black patients chose CPM compared to 43.5% of White patients (Bonferroni corrected p-value♯αμπ;λτ;0.001). Women who underwent CPMs had a trend for a larger median weight of the breasts, although this did not reach statistical significance (p = 0.09).

            Figure 1:
             Contralateral prophylactic mastectomy (CPM) vs unilateral mastectomy (UM) according to race.

            The histopathology of the breasts, including breast weight, primary tumour histology, histology of the contralateral side and TNM staging of the tumour, is shown in Table 3. One patient's histopathology was not captured, and only 211/299 patients had data on neoadjuvant therapy.

            Table 3:
            Histopathology of the breast according to CPM status
            Parameter, n (%)All (n = 298)UM (n = 239)CPM (n = 59)P-value
            Histology of tumour
            Ductal Carcinoma In Situ18 (6.0)15 (6.3)3 (5.2)
            Invasive Ductal Carcinoma230 (77.2)184 (76.7)46 (79.3)0.69
            Invasive Lobular Carcinoma10 (3.4)7 (2.9)3 (5.2)
            Other subtypes40 (13.4)34 (14.2)6 (10.3)
            Histology of CPM
            Ductal carcinoma in situ1 (1.7%)-1 (1.7%)-
            No Invasive Malignancy47 (81.0%)-47 (81.0%)
            NA* 10 (17.2%)-10 (17.2%)
            TNM stage
            Stage 0-2a (early)129 (43.3%)98 (41.0%)31 (52.5%)0.14
            Stage 2b-4 (late)169 (56.7%)141 (59.0%)28 (47.5%)
            Neoadjuvant chemotherapy n = 211
            Yes161 (76.3%)133 (54.7%)29 (49.2%)>0.99
            No50 (23.7%)42 (17.3%)9 (15.3%)

            Abbreviations: CPM, contralateral prophylactic mastectomy; UM, unilateral mastectomy.

            *

            This applies to the unilateral mastectomy patients

            There was no significant association between the UM or CPM group for each of the following variables: Histology of tumour (p-value = 0.69), TNM stage (p-value = 0.14) and neoadjuvant chemotherapy (p-value >0.99).

            The population with CPM were predominantly White, with the mean weight of the breast being larger than that of the UM counterparts and the median age being younger. Pathologically, most of the population had invasive ductal carcinoma, were T2 N +, thus either Stage IIb or IIIa, and had had neoadjuvant chemotherapy. Of this group, only one patient was found to have a contralateral malignancy.

            Discussion

            International trends influence patients’ decision-making from both a patient's and a health professional's point of view. In the era of increased access to information, health professionals must not be deterred from practising evidence-based medicine. There always, however, lies a caveat to applying blanket medical advice to diverse communities.

            The Department of Health provides public and private health services in South Africa. Citizens who access the public health service are of a lower socioeconomic standing.(23) Adequate, evidence-based health care is provided to all patients despite their socioeconomic status. The need to stratify patients according to ‘H’ status allows them to be billed according to their affordability. In this study, we did not expect to see a discrepancy between the UM and CPM populations based on socioeconomic standing, as the majority of this population is of similar economic standing.

            International studies have shown that White women were more likely than any other race to have CPM. This finding was also demonstrated in our study. The varying levels of education and access to information among the patients could influence this. Owing to the country's Apartheid history, significant discrepancies in equality still exist. The country's White population had access to better education and health care before establishing democracy.(23) Despite only 23.2% of White women in the study population, more than half the CPM procedures were performed in this group (50.9%). It is, however, possible that there are also other culture-specific influences that this study does not elicit from the various ethnic groups.

            We hypothesized that women with larger breasts would more likely choose a CPM procedure. Despite the CPM group having a larger median breast weight, this did not reach statistical significance. This finding is consistent with the literature that did not find this factor influential on CPM choice.

            A higher percentage of patients post neoadjuvant chemotherapy still opted for UM, which, although not statistically significant, is inconsistent with international studies which demonstrated neoadjuvant chemotherapy as a factor favouring CPM.(12,15)

            The cancer stage at presentation was higher in our study than in the rest of the world.(24) Furthermore, a high percentage (56.7) of patients were found to have late-stage (2b–4) breast cancer. It can, however, be noted that the population that underwent CPM mastectomies had the highest percentage early stage (stage 0-2a) compared to the late stage (stage 2b-4). This finding is consistent with previous reports showing that lower-stage tumours were present in patients who had chosen CPM.

            The most prevalent histology of the total population was invasive ductal carcinoma, which was reflected in both CPM and UM procedures. Previous studies, however, have reported that patients choosing CPM had invasive lobular carcinoma as the prevalent histology. The incidence of contralateral breast cancer is higher for invasive lobular carcinoma, and thus, the preservation of the contralateral breast is less frequent.(25) In the current study, only 30% of patients with invasive lobular carcinoma had a CPM, suggesting that the biology of the tumour did not play a significant role in influencing the decision to undergo CPM. This finding may be related to the fact that the health practitioner, in line with the ethical considerations of the evidence, would not routinely advise CPM, even in discussing the risk of contralateral involvement of invasive lobular carcinoma.(26)

            A history of neoadjuvant chemotherapy has been associated with electing CPM. In this study, the analysis of this factor was limited because almost 30% of the study population did not have the timing of their chemotherapy documented. Of the patients where it was reported, 76% had neoadjuvant chemotherapy, and in this group, unlike the trend in international literature, only a small percentage (17.9%) had CPM. This rate is similar to the group who underwent CPM without neoadjuvant chemotherapy (17.6%).

            Limitations of the Study and Alternative Approaches

            The limitations in the study arose from incomplete file records. In the public sector, there are significant limitations to the assessment of the socio-economic status of a patient based on UPFS, or ‘H’ status, as the latter is based on the evaluation of income, which in turn is difficult to accurately verify on admission to the hospital. Even though the setting of this study was an urban clinic, rural patients may have unwittingly been included as they often travel far due to the increased access to healthcare in urban areas; this may have impacted their H-status.

            Conclusion

            The demographic and histopathological characteristics of breast cancer which influence the choice of CPM in the South African context have some similarities to those in the international literature in that White and younger women more often choose CPM compared to other racial groups. In future, with the continuation of monitoring of our patients’ characteristics, increasing access to information, and advances in breast cancer detection and management, the decision to choose CPM may no longer carry a racial bias. Of concern is the more advanced stage of breast cancer at presentation in our study as compared to international studies. Public health awareness and screening measures need to be strengthened significantly, especially for the indigent population that relies solely on the public healthcare system in South Africa.

            All authors have contributed as stipulated by the authorship guidelines. There are no conflicts of interest to declare, and the study did not require funding.

            References

            1. , , , et al. Global Cancer Statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. in press. The online GLOBOCAN 2018 database is available at http://gco.iarc.fr/

            2. , , , et al. Contralateral prophylactic mastectomy (CPM) consensus statement from the American Society of Breast Surgeons: data on CPM outcomes and risks. Ann Surg Oncol. 2016; 23:3100–3105.

            3. World Health Organisation. South Africa Cancer Cases [Internet] 2020. Available from: https://gco.iarc.fr/today/data/factsheets/populations/710-south-africa-fact-sheets.pdf. Accessed 29 July 2020 .

            4. , , , et al. Latest world cancer statistics global cancer burden rises to 14.1 million new cases in 2012: marked increase in breast cancers must be addressed. Int Agency Res Cancer. 2013; 223:1–3.

            5. American Cancer Society. Breast Cancer Risk Factors You Cannot Change [Internet] 2020. Available from: https://www.cancer.org/cancer/breast-cancer/risk-and-prevention/breast-cancer-risk-factors-you-cannot-change.html

            6. , , . BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer. 2012; 12:68–78.

            7. , , The contralateral prophylactic mastectomy decision-making process. Am Soc Plast Surg Nurs. 2013; 33:11–21.

            8. , , , et al. Predictors that influence contralateral prophylactic mastectomy election among women with ductal carcinoma in situ who were evaluated for BRCA genetic testing. Ann Surg Oncol. 2014; 21:3466–3472.

            9. , , , et al. Variation in contralateral prophylactic mastectomy rates according to racial groups in young women with breast cancer 1998–2011. A Report from The National Cancer Data Base. J Am Coll Surg. 2015; 22:187–196.

            10. , , , et al. Defining the relationship between patient decisions to undergo breast reconstruction and contralateral prophylactic mastectomy. Plast Reconst Surg. 2015; 135:661–670.

            11. , , , et al. Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J Clin Oncol. 2007; 25:5203–5209.

            12. , , , et al. Use of immediate breast reconstruction and choice for contralateral prophylactic mastectomy. Surgery. 2016; 159:1199–1209.

            13. , , , et al. Increasing trend of contralateral prophylactic mastectomy: what are the factors behind this phenomenon? Surgeon. 2014; 12:316–322.

            14. , , , et al. Trends in use of contralateral prophylactic mastectomy by racial/ethnic group and ER/PR status among patients with breast cancer: a SEER population-based study. Cancer Epidemiol. 2016; 42:24–31.

            15. , , , et al. Higher stage of disease is associated with bilateral mastectomy among patients with breast cancer: a population-based survey. Clin Breast Cancer. 2016; 16:105–112.

            16. , , , et al. ‘Taking control of cancer’: understanding women's choice for mastectomy. Ann Surg Oncol. 2015; 22:383–391.

            17. , , , et al. Contralateral prophylactic mastectomy: a systematic review of patient-reported factors and psychological predictors influencing choice and satisfaction. Breast. 2016; 28:107–120.

            18. , , , et al. Increasing incidence of bilateral mastectomies: the patient perspective. Am J Surg. 2011; 201:615–618.

            19. , What made her give up her breasts: a qualitative study on decisional considerations for contralateral prophylactic mastectomy among breast cancer survivors undergoing BRCA1/2 genetic testing. Asian Pac J Cancer Prev. 2012; 13:2241–2247.

            20. , , , et al. Review of risk factors for the development of contralateral breast cancer. Am J Surg. 2013; 206:704–708.

            21. , , , et al. Breast reconstruction in bilateral prophylactic mastectomy patients; factors that influence decision making. J Plast Reconst Aesthet Surg. 2012; 65:1481–1489.

            22. UPFS Tariff Committee National Department of Health (NDoH) Uniform Patient Fee Schedule for Paying Patients Attending Public Hospitals, User Guide Version 1 [Internet] 2009 Edition pages 2–3. Available from: www.health.gov.za

            23. , , Access to quality health care in South Africa: is the health sector contributing to addressing the inequality challenge? 2014. Available at: https://www.parliament.gov.za

            24. , , , et al. An update on the management of breast cancer in Africa. Infect Agents Cancer. 2017; 12:13. doi: 10.1186/s13027-017-0124-y.

            25. , , , Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res. 2004; 6 ( 3 ):R149–R156. Epub 17 February 2004.

            26. , , , The rise in bilateral mastectomies: evidence, ethics, and physician's role. Breast. 2016; 29:161.

            Author and article information

            Journal
            WUP
            Wits Journal of Clinical Medicine
            Wits University Press (5th Floor University Corner, Braamfontein, 2050, Johannesburg, South Africa )
            2618-0189
            2618-0197
            04 March 2024
            : 6
            : 1
            : 19-24
            Affiliations
            [1]Department of Surgery, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand
            Author notes
            [* ] Correspondence to: phum.ndwambi@ 123456gmail.com
            Author information
            https://orcid.org/0000-0001-7059-7277
            https://orcid.org/0000-0001-8275-038X
            https://orcid.org/0000-0002-3604-7682
            Article
            WJCM
            10.18772/26180197.2024.v6n1a3
            753533e7-002d-4c97-9bf0-f2b2351a1729
            WITS

            Distributed under the terms of the Creative Commons Attribution Noncommercial NoDerivatives License https://creativecommons.org/licenses/by-nc-nd/4.0/, which permits noncommercial use and distribution in any medium, provided the original author(s) and source are credited, and the original work is not modified.

            History
            Categories
            Research Article

            General medicine,Medicine,Internal medicine
            Breast cancer,breast cancer histology,unilateral mastectomy,prophylactic mastectomy

            Comments

            Comment on this article